Ignite Creation Date:
2025-12-25 @ 4:09 AM
Ignite Modification Date:
2025-12-26 @ 3:07 AM
Study NCT ID:
NCT06625320
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-12
First Post:
2024-09-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor:
Revolution Medicines, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-10-16
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12
Completion Date Type:
ESTIMATED
First Submit Date:
2024-09-20
First Submit QC Date:
None
Study First Post Date:
2024-10-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-05
Last Update Post Date:
2025-12-12
Last Update Post Date Type:
ESTIMATED